Cargando…

Foetal Haemoglobin as a Marker of Bone Marrow Suppression Secondary to Anti-Kell Alloimmunisation

Anti-Kell alloimmunisation is a potentially severe minor blood group type incompatibility, not only as a cause of haemolytic disease of the foetus and newborn, but also due to the destruction of red blood cells (RBC) and mature form in the bone marrow with the subsequent hyporegenerative anaemia. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales Painamil, Rodrigo Alfredo, de Aledo-Castillo, José Manuel González, Teresa-Palacio, Marta, Argudo-Ramírez, Ana, López-Galera, Rosa M., Paredes-Fuentes, Abraham J., Aldecoa-Bilbao, Victoria, Alsina-Casanova, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204544/
https://www.ncbi.nlm.nih.gov/pubmed/37218889
http://dx.doi.org/10.3390/ijns9020024
_version_ 1785045859158720512
author Morales Painamil, Rodrigo Alfredo
de Aledo-Castillo, José Manuel González
Teresa-Palacio, Marta
Argudo-Ramírez, Ana
López-Galera, Rosa M.
Paredes-Fuentes, Abraham J.
Aldecoa-Bilbao, Victoria
Alsina-Casanova, Miguel
author_facet Morales Painamil, Rodrigo Alfredo
de Aledo-Castillo, José Manuel González
Teresa-Palacio, Marta
Argudo-Ramírez, Ana
López-Galera, Rosa M.
Paredes-Fuentes, Abraham J.
Aldecoa-Bilbao, Victoria
Alsina-Casanova, Miguel
author_sort Morales Painamil, Rodrigo Alfredo
collection PubMed
description Anti-Kell alloimmunisation is a potentially severe minor blood group type incompatibility, not only as a cause of haemolytic disease of the foetus and newborn, but also due to the destruction of red blood cells (RBC) and mature form in the bone marrow with the subsequent hyporegenerative anaemia. In severe cases and when the foetus shows signs of anaemia, an intrauterine transfusion (IUT) may be necessary. When repeated, this treatment can suppress erythropoiesis and worsen the anaemia. We report the case of a newborn who required four IUTs plus an additional RBC transfusion at one month of life due to late onset anaemia. The identification of an adult haemoglobin profile with a complete absence of foetal haemoglobin in the patient’s newborn screening samples at 2 and 10 days of life warned us of a possible late anaemia. The newborn was successfully treated with transfusion, oral supplements and subcutaneous erythropoietin. A blood sample taken at 4 months of life showed the expected haemoglobin profile for that age with a foetal haemoglobin of 17.7%. This case illustrates the importance of a close follow-up of these patients, as well as the usefulness of the haemoglobin profile screening as a tool for anaemia assessment.
format Online
Article
Text
id pubmed-10204544
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102045442023-05-24 Foetal Haemoglobin as a Marker of Bone Marrow Suppression Secondary to Anti-Kell Alloimmunisation Morales Painamil, Rodrigo Alfredo de Aledo-Castillo, José Manuel González Teresa-Palacio, Marta Argudo-Ramírez, Ana López-Galera, Rosa M. Paredes-Fuentes, Abraham J. Aldecoa-Bilbao, Victoria Alsina-Casanova, Miguel Int J Neonatal Screen Case Report Anti-Kell alloimmunisation is a potentially severe minor blood group type incompatibility, not only as a cause of haemolytic disease of the foetus and newborn, but also due to the destruction of red blood cells (RBC) and mature form in the bone marrow with the subsequent hyporegenerative anaemia. In severe cases and when the foetus shows signs of anaemia, an intrauterine transfusion (IUT) may be necessary. When repeated, this treatment can suppress erythropoiesis and worsen the anaemia. We report the case of a newborn who required four IUTs plus an additional RBC transfusion at one month of life due to late onset anaemia. The identification of an adult haemoglobin profile with a complete absence of foetal haemoglobin in the patient’s newborn screening samples at 2 and 10 days of life warned us of a possible late anaemia. The newborn was successfully treated with transfusion, oral supplements and subcutaneous erythropoietin. A blood sample taken at 4 months of life showed the expected haemoglobin profile for that age with a foetal haemoglobin of 17.7%. This case illustrates the importance of a close follow-up of these patients, as well as the usefulness of the haemoglobin profile screening as a tool for anaemia assessment. MDPI 2023-04-23 /pmc/articles/PMC10204544/ /pubmed/37218889 http://dx.doi.org/10.3390/ijns9020024 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Morales Painamil, Rodrigo Alfredo
de Aledo-Castillo, José Manuel González
Teresa-Palacio, Marta
Argudo-Ramírez, Ana
López-Galera, Rosa M.
Paredes-Fuentes, Abraham J.
Aldecoa-Bilbao, Victoria
Alsina-Casanova, Miguel
Foetal Haemoglobin as a Marker of Bone Marrow Suppression Secondary to Anti-Kell Alloimmunisation
title Foetal Haemoglobin as a Marker of Bone Marrow Suppression Secondary to Anti-Kell Alloimmunisation
title_full Foetal Haemoglobin as a Marker of Bone Marrow Suppression Secondary to Anti-Kell Alloimmunisation
title_fullStr Foetal Haemoglobin as a Marker of Bone Marrow Suppression Secondary to Anti-Kell Alloimmunisation
title_full_unstemmed Foetal Haemoglobin as a Marker of Bone Marrow Suppression Secondary to Anti-Kell Alloimmunisation
title_short Foetal Haemoglobin as a Marker of Bone Marrow Suppression Secondary to Anti-Kell Alloimmunisation
title_sort foetal haemoglobin as a marker of bone marrow suppression secondary to anti-kell alloimmunisation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204544/
https://www.ncbi.nlm.nih.gov/pubmed/37218889
http://dx.doi.org/10.3390/ijns9020024
work_keys_str_mv AT moralespainamilrodrigoalfredo foetalhaemoglobinasamarkerofbonemarrowsuppressionsecondarytoantikellalloimmunisation
AT dealedocastillojosemanuelgonzalez foetalhaemoglobinasamarkerofbonemarrowsuppressionsecondarytoantikellalloimmunisation
AT teresapalaciomarta foetalhaemoglobinasamarkerofbonemarrowsuppressionsecondarytoantikellalloimmunisation
AT argudoramirezana foetalhaemoglobinasamarkerofbonemarrowsuppressionsecondarytoantikellalloimmunisation
AT lopezgalerarosam foetalhaemoglobinasamarkerofbonemarrowsuppressionsecondarytoantikellalloimmunisation
AT paredesfuentesabrahamj foetalhaemoglobinasamarkerofbonemarrowsuppressionsecondarytoantikellalloimmunisation
AT aldecoabilbaovictoria foetalhaemoglobinasamarkerofbonemarrowsuppressionsecondarytoantikellalloimmunisation
AT alsinacasanovamiguel foetalhaemoglobinasamarkerofbonemarrowsuppressionsecondarytoantikellalloimmunisation